Placebo + AZD3480 + AZD3480

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

May 1, 2008 → Jul 1, 2009

About Placebo + AZD3480 + AZD3480

Placebo + AZD3480 + AZD3480 is a phase 2 stage product being developed by AstraZeneca for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00683462. Target conditions include ADHD.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (2) Active (10)
atomoxetineEli LillyApproved
Strattera (atomoxetine)Eli LillyApproved
Atomoxetine + placeboEli LillyApproved
atomoxetine (Strattera)Eli LillyApproved
🔄dasotraline + PlaceboSumitomo PharmaPhase 3
🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00683462Phase 2Completed

Competing Products

20 competing products in ADHD

See all competitors